Related Experiment Videos
Screening for and treatment of hypercholesterolaemia--a review
1Department of Community, Occupational and Family Medicine, National University of Singapore, Singapore.
Insights
Screening for high cholesterol (hypercholesterolaemia) is complex. While statins show promise for secondary prevention, more research is needed before recommending widespread primary screening.
Area of Science:
- Cardiology
- Preventive Medicine
- Public Health
Background:
- Hypercholesterolaemia is a significant risk factor for coronary heart disease (CHD).
- Initial mass screening recommendations for serum cholesterol levels ≥ 6.5 mmol/L have been refined due to treatment trial outcomes.
- Cost-effectiveness and evidence of benefit are key considerations in screening strategies.
Purpose of the Study:
- To evaluate the evolving strategies for screening and treating hypercholesterolaemia.
- To assess the evidence supporting mass screening versus targeted screening based on risk factors.
- To review the efficacy of lipid-lowering drugs, particularly statins, in different patient populations.
Main Methods:
- Review of clinical trials on hypercholesterolaemia treatment and screening.
- Analysis of data on lipid-lowering drugs, including statins.
- Evaluation of evidence for secondary prevention versus primary prevention.
Main Results:
- Lipid-lowering drugs demonstrate clear benefits for secondary prevention in patients with existing CHD or major risk factors.
- Statins show greater efficacy compared to other lipid-lowering agents.
- A recent trial suggests potential benefits of primary prevention in middle-aged males, warranting further investigation.
Conclusions:
- Current recommendations favor screening for hypercholesterolaemia in individuals with CHD or major risk factors (hypertension, diabetes, smoking, family history).
- While statins enhance secondary prevention, evidence for routine primary prevention screening in the general population remains inconclusive.
- Further long-term follow-up and local health assessments are necessary before advocating for mass primary screening for hypercholesterolaemia.
Abstract:
The screening for and treatment of hypercholesterolaemia is still a complex and controversial issue. As hypercholesterolaemia is a major risk factor for coronary heart disease (CHD), there was initially much enthusiasm for mass screening with intervention recommended for persons with serum cholesterol levels > or = 6.5 mmol/L. However, trials of treatment of hypercholesterolaemia using lipid lowering drugs showed overall benefit (i.e. reduced all-cause mortality) only for persons with pre-existing CHD (secondary prevention) or other major risk factors. For this and other reasons (e.g. cost effectiveness) screening for hypercholesterolaemia has been recommended for persons with CHD or major risk factors (family history of premature coronary heart disease, cigarette smoking, hypertension, and diabetes mellitus). Recent trials with statins have shown greater benefit than with other lipid lowering drugs, confirming the benefits of secondary prevention. In addition, one trial has shown overall benefit after 5 years for middle-aged hypercholesterolaemic males without a previous myocardial infarction, raising the possibility of mass screening. However, longer follow-up of a number of trials of primary prevention including on persons without risk factors together with a full assessment of the local situation with regards to hypercholesterolaemia is needed before mass screening can be recommended.